Larimar Shares Soar 66% on FDA Breakthrough Designation and Upgraded Targets
Larimar Therapeutics shares surged over 66% after Citigroup raised its price target from $12 to $14 and Wedbush reiterated an $11 outperform rating. The FDA granted Breakthrough Therapy designation to nomlabofusp for Friedreich's ataxia, driving a 106% year-over-year gain and lifting the stock 72.5% above its 50-day moving average.
1. Analysts Raise Price Targets and Ratings
Citigroup maintained a Buy rating on Larimar Therapeutics and increased its price target from $12 to $14, while Wedbush reaffirmed an Outperform rating with an $11 target, signaling growing confidence among major brokerage firms.
2. FDA Breakthrough Designation Speeds Nomlabofusp Review
The FDA granted Breakthrough Therapy designation to nomlabofusp for treating Friedreich's ataxia, aiming to accelerate clinical development and regulatory review for this lead candidate addressing a serious, unmet medical need.
3. Stock Jumps and Technical Indicators Signal Momentum
Shares of Larimar climbed over 66% to a new 52-week high, delivering a 106.15% year-over-year return; the stock trades 72.5% above its 50-day SMA, with an RSI of 58.66 and the MACD above its signal line indicating sustained bullish momentum.
4. Outperformance Against Healthcare Sector
While the broader Healthcare sector dipped 0.11%, Larimar’s more than 66% surge highlights its standout performance, supported by a moderate momentum score of 54.24 against a backdrop of sector weakness.